Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Onychomycosis (Tinea Unguium) - Overview
Onychomycosis (Tinea Unguium) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Onychomycosis (Tinea Unguium) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Onychomycosis (Tinea Unguium) - Companies Involved in Therapeutics Development
Acea Biotech Inc
Almirall SA
Amtixbio Co Ltd
ASCIL Biopharm
Blueberry Therapeutics Ltd
CSA Biotechnologies LLC
DermBiont Inc
Exodos Life Sciences Limited Partnership
Hallux Inc
Hexima Ltd
Infextious Therapeutic
Kaken Pharmaceutical Co Ltd
Moberg Pharma AB
Mycovia Pharmaceuticals Inc
L Pharmaceuticals Ltd
Nektr Technologies Ltd
Novabiotics Ltd
Photomic GmbH & Co KG
SaNOtize Research and Development Corp
TTY Biopharm Co Ltd
Turn Therapeutics Inc
Onychomycosis (Tinea Unguium) - Drug Profiles
A-31S - Drug Profile
Product Description
Mechanism Of Action
History of Events
aminolevulinic acid hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
Amphotericin B sodium - Drug Profile
Product Description
Mechanism Of Action
ATB-1651 - Drug Profile
Product Description
Mechanism Of Action
BB-0305 - Drug Profile
Product Description
Mechanism Of Action
History of Events
benzalkonium chloride + polyhexanide - Drug Profile
Product Description
Mechanism Of Action
DBI-001 - Drug Profile
Product Description
Mechanism Of Action
eficozole - Drug Profile
Product Description
Mechanism Of Action
History of Events
ELS-160 - Drug Profile
Product Description
Mechanism Of Action
IFX-103 - Drug Profile
Product Description
Mechanism Of Action
KP-607 - Drug Profile
Product Description
Mechanism Of Action
L-3210 - Drug Profile
Product Description
Mechanism Of Action
NORS-0791 - Drug Profile
Product Description
Mechanism Of Action
NP-213 - Drug Profile
Product Description
Mechanism Of Action
History of Events
onymed - Drug Profile
Product Description
Mechanism Of Action
otesecozole - Drug Profile
Product Description
Mechanism Of Action
History of Events
P-3058 - Drug Profile
Product Description
Mechanism Of Action
History of Events
pezadeftide - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Disrupt Cell Membrane for Onychomycosis - Drug Profile
Product Description
Mechanism Of Action
History of Events
terbifine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
terbifine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
terbifine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
TTY-W - Drug Profile
Product Description
Mechanism Of Action
Onychomycosis (Tinea Unguium) - Dormant Projects
Onychomycosis (Tinea Unguium) - Discontinued Products
Onychomycosis (Tinea Unguium) - Product Development Milestones
Featured News & Press Releases
Jan 12, 2022: Hallux starts phase 2 clinical study of novel subungual gel for onychomycosis
Dec 23, 2021: The Medical Products Agency in Sweden will be reference member state for Moberg Pharma’s European registration application
Sep 22, 2021: Moberg Pharma receives approval from the EMA’s Paediatric Committee
Aug 24, 2021: Chi patent for pezadeftide granted ACCESS CHI Biotech Forum presentation investor webir on 2 September 2021
Jul 26, 2021: Hexima: Completion of enrolment in phase IIb clinical trial
Jul 15, 2021: Hexima: Presentation of Phase I/IIa study data at American Podiatric Medical Association (APMA) and Investor Webir
Jul 14, 2021: Hexima: Grant of European Patent over HXP124
Jun 10, 2021: Moberg Pharma: Phase 3-results for MOB-015 published in JAAD
May 20, 2021: Hexima announces INN desigtion for HXP124
May 12, 2021: Hexima : Grant of Australian patent over HXP124
Apr 26, 2021: Hexima to present at American Podiatric Medical Association annual conference
Mar 10, 2021: Acceptance of Clefin/Jublia (eficozole) for regulatory review in Chi
Jan 07, 2021: Updated timeline to phase IIb results
Oct 14, 2020: Moberg Pharma intends to submit a registration application in Europe in 2021
Sep 14, 2020: Launch of Jublia, a treatment for tinea unguium, in Macau
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Onychomycosis (Tinea Unguium), 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Onychomycosis (Tinea Unguium), 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Onychomycosis (Tinea Unguium) - Pipeline by Acea Biotech Inc, 2022
Onychomycosis (Tinea Unguium) - Pipeline by Almirall SA, 2022
Onychomycosis (Tinea Unguium) - Pipeline by Amtixbio Co Ltd, 2022
Onychomycosis (Tinea Unguium) - Pipeline by ASCIL Biopharm, 2022
Onychomycosis (Tinea Unguium) - Pipeline by Blueberry Therapeutics Ltd, 2022
Onychomycosis (Tinea Unguium) - Pipeline by CSA Biotechnologies LLC, 2022
Onychomycosis (Tinea Unguium) - Pipeline by DermBiont Inc, 2022
Onychomycosis (Tinea Unguium) - Pipeline by Exodos Life Sciences Limited Partnership, 2022
Onychomycosis (Tinea Unguium) - Pipeline by Hallux Inc, 2022
Onychomycosis (Tinea Unguium) - Pipeline by Hexima Ltd, 2022
Onychomycosis (Tinea Unguium) - Pipeline by Infextious Therapeutic, 2022
Onychomycosis (Tinea Unguium) - Pipeline by Kaken Pharmaceutical Co Ltd, 2022
Onychomycosis (Tinea Unguium) - Pipeline by Moberg Pharma AB, 2022
Onychomycosis (Tinea Unguium) - Pipeline by Mycovia Pharmaceuticals Inc, 2022
Onychomycosis (Tinea Unguium) - Pipeline by NAL Pharmaceuticals Ltd, 2022
Onychomycosis (Tinea Unguium) - Pipeline by Nektr Technologies Ltd, 2022
Onychomycosis (Tinea Unguium) - Pipeline by Novabiotics Ltd, 2022
Onychomycosis (Tinea Unguium) - Pipeline by Photonamic GmbH & Co KG, 2022
Onychomycosis (Tinea Unguium) - Pipeline by SaNOtize Research and Development Corp, 2022
Onychomycosis (Tinea Unguium) - Pipeline by TTY Biopharm Co Ltd, 2022
Onychomycosis (Tinea Unguium) - Pipeline by Turn Therapeutics Inc, 2022
Onychomycosis (Tinea Unguium) - Dormant Projects, 2022
Onychomycosis (Tinea Unguium) - Dormant Projects, 2022 (Contd..1)
Onychomycosis (Tinea Unguium) - Discontinued Products, 2022